Palobiofarma receives milestone payment from Novartis

by Palobiofarma

The milestone payment is the first from the licensing agreement between the two companies. Under the terms of that agreement, which was signed in September 2015, Novartis has exclusive development and...

Read more

Palobiofarma signs licensing agreement to develop novel adenosine-based immuno-oncology treatments

by Palobiofarma

Under the terms of the agreement Novartis will acquire exclusive global rights to develop, manufacture and commercialize Palobiofarma´s adenosine A2Areceptor antagonist PBF-509, currently entering Ph...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Remedi is born from the fusion of the co...

by Regenera Activa Worldwide

Regenera Activa Worldwide and Rigenera HBW, biotech firms specializing...

Photos Stream